Skip to main content
Atrás
Watch Compare

Apimeds Pharmaceuticals US, Inc.

Calidad de datos: 83%
APUS
NYSE Manufacturing Chemicals
$1.88
$0.00 (0.00%)
Cap. Mercado: 23.64 M
Precio
$1.88
Cap. Mercado
23.64 M
Rango del Día
$1.77 — $1.89
Rango de 52 Semanas
$1.61 — $40.31
Volumen
31,534
Apertura $1.69
Promedio 50D / 200D
$13.56
86.14% below
Promedio 50D / 200D
$18.05
89.59% below

Quick Summary

Puntos Clave

Negative free cash flow of -5.88 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-69.68%
Below sector avg (-51.02%)
ROIC-54.27%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio8.34
Interest Coverage-33.21

Valoración

PE (TTM)
-3.79
Below sector avg (-1.98)
P/B Ratio2.90
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E -3.8 -2.0
P/B 2.9 5.1
ROE % -69.7 -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -6.24 M
ROE -69.68% ROA -63.00%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5.88 M
ROIC -54.27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.34
Interest Coverage -33.21 Asset Turnover N/A
Working Capital 8.00 M Tangible Book Value 8.16 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.79 Forward P/E N/A
P/B Ratio 2.90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.86%
Market Cap 23.64 M Enterprise Value 16.66 M
Per Share
EPS (Diluted TTM) -0.65 Revenue / Share N/A
FCF / Share -0.47 OCF / Share -0.46
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 94.25%
SBC-Adj. FCF -5.95 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024
Revenue —
Net Income -1.39 M
EPS (Diluted) -0.18
Gross Profit —
Operating Income -1.28 M
EBITDA —
R&D Expenses 98,544.0
SG&A Expenses —
D&A —
Interest Expense 117,719.0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2024
Total Assets 13,057.0
Total Liabilities 1.37 M
Shareholders' Equity -1.36 M
Total Debt 20,000.0
Cash & Equivalents 3,455.0
Current Assets 13,057.0
Current Liabilities 1.02 M